This article describes the case of an individual prescribed buprenorphine for opioid use disorder (OUD) who did not achieve treatment stability at the maximum dose allowed by the patient’s insurer of 24 mg daily. The patient’s treatment team conducted pharmacogentic testing and determined the patient had a phenotype that caused his body to rapidly metabolize his medication and reduced its effectiveness. On a higher dose of 32 mg the patient stabilized and dramatically reduced relapse events. The paper also includes recommendations for implementing pharmacogenetics considerations in medication assisted treatment for OUD.
Funding Sources: Howard University Research Centers in Minority Institutions Program and National Institute on Minority Health and Health Disparities
Pharmacogenomics-Guided Policy in Opioid Use Disorder Management: An Ethically-Diverse Case-Based Approach
A study of individual genetic differences that may affect response to medication assisted treatment and require dose adjustment based on patient phenotype